1. S68 Phase 1 trial of an intranasal respiratory syncytial virus (rsv) subunit candidate vaccine: safety results from the muc-syngem study. (15th November 2017) Authors: Vlachantoni, I; Ascough, S; Grimaldi, R; Leenhouts, K; Chiu, C; Openshaw, P Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗